Abstract: This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease, especially disease caused by C. perfringens and Eimeria in animals. The invention also relates to improving the feed conversion ratio in a food producing animal by administering berberine compositions.
Type:
Application
Filed:
January 2, 2018
Publication date:
December 21, 2023
Applicant:
IRP Health Pty Ltd
Inventors:
David Xiang YU, Zhicheng XIAO, Colin William POUTON, Zhiyong HE
Abstract: This invention relates to berberine alkaloids, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals, particularly Lawsonia infection. In particular, the invention relates to berberine alkaloids, formulations thereof, and their application as antimicrobial agents in the prevention and/or treatment of infectious disease including bacterial, viral, parasitic or fungal infections, and for improving feed conversion ratio in food-producing animals. Also described is the use of berberine alkaloids as feed preservatives, added to feed compositions, and used in combination with further agents suitable for treating infectious disease.
Type:
Application
Filed:
March 28, 2018
Publication date:
October 28, 2021
Applicant:
IRP Health Pty Ltd
Inventors:
David Xiang YU, Zhicheng XIAO, Colin William POUTON, Zhiyong HE
Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.
Type:
Application
Filed:
May 29, 2019
Publication date:
July 22, 2021
Applicant:
IRP Health Pty Ltd
Inventors:
Zhicheng XIAO, David Xiang YU, Colin William POUTON, Zhiyong HE